BD's Revello Stent Posts Strong AGILITY Data, But Overhangs Persist

What happened

BD announced positive nine-month results from its AGILITY trial for the Revello drug-coated stent in treating peripheral artery disease, showing high patency and low target lesion revascularization rates. The data supports Revello's efficacy and safety in the femoropopliteal segment, potentially strengthening BD's competitive position in the peripheral vascular market. This reinforces BD's Interventional segment, which already posts strong margins (39.9% in Q3 2026) and growth, and aligns with a broader tailwind in interventional devices. However, the trial is company-sponsored and short-term; longer-term data and real-world adoption will be needed to confirm the stent's differentiation against rivals like Boston Scientific's Eluvia or Medtronic's IN.PACT. The news does not change the overall investment thesis, which remains constrained by tariff headwinds, BioPharma Systems growth uncertainty, and quality remediation overhangs.

Implication

The AGILITY results provide another data point supporting BD's Interventional momentum, but investors should not extrapolate this into a re-rating without seeing sustained conversion to revenue share gains. The Interventional segment's high margin and growth are key contributors, yet the overall company valuation at 53x P/E and 13.1x EV/EBITDA already discounts a constructive outcome. Tariff adverse-impact language, BioPharma Systems' negative FX-neutral growth in Q2, and ongoing Alaris remediation remain more material to the stock's direction over the next 6-12 months. The thesis only improves if BioPharma Systems turns positive FX-neutral and tariff costs are quantified as offset, or if quality issues are cleanly resolved. Thus, while Revello is a positive incremental, it is unlikely to move the needle on the WAIT rating; attractive entry remains near $160 and re-assessment hinges on quarterly proof points rather than single trial news.

Thesis delta

The Revello data marginally strengthens the bull case for Interventional but does not address the three main overhangs: tariffs, BioPharma Systems growth, and quality/remediation. The core thesis remains unchanged: BD's durable franchise is offset by valuation and unresolved execution issues, keeping the stock at WAIT. The probability of the bull scenario might see a slight uptick if Revello gains share, but without broader evidence, the base case holds.